Abstract
The antioxidant effects of Sonchus brachyotus DC. extract (SBE) likely involve multi-pathway and multi-target mechanisms, consistent with the combinatorial properties of its herbal constituents. This study explores how SBE protects against systemic damage caused by acute ethanol consumption by integrating multiple "omics" layers, revealing a complex regulatory network involving gut fungi, serum metabolites, and host gene expression. These findings lay a foundation for subsequent research into natural antioxidants and their systemic protective mechanisms.
Introduction
Oxidative stress is a primary driver of various inflammatory and neurodegenerative diseases. While ethanol is a well-known inducer of acute oxidative stress, the systemic mechanisms through which natural antioxidants provide protection are often oversimplified as mere "radical scavenging." Current research often focuses almost exclusively on gut bacteria, neglecting the mycobiome (fungi) and the tripartite interaction between microbes, metabolites, and host genes. This study seeks to map the full "interactome" to explain how SBE exerts its protective effects across multiple organs, including the gut, liver, and brain.
Methods
The researchers used an ICR mouse model of ethanol-induced acute oxidative stress, treating groups with varying doses of SBE (200–600 mg/kg). A sophisticated multi-omics approach was employed to capture the systemic response:
- Microbiome & Mycobiome: 16S rRNA (bacteria) and ITS (fungi) sequencing of cecal contents.
- Metabolomics: LC-QTOF-MS untargeted analysis of mice serum.
- Transcriptomics: RNA-Seq of colon tissue to identify differentially expressed genes (DEGs).
- In Silico Analysis: Molecular docking to simulate the binding affinity of SBE’s bioactive components (trigonelline, mesaconic acid, and salicylic acid) with target proteins.
- Validation: Histological staining (H&E), immunofluorescence for tight junction proteins, and qRT-PCR/Western Blotting to confirm gene and protein expression levels.
Key Insights and Results
The study revealed that SBE mitigates ethanol-induced oxidative stress by remodeling the "fungi-metabolite-gene" axis across the fungi-gut-brain-liver axis.
The Role of the Mycobiome
Surprisingly, gut fungi showed a stronger correlation with oxidative stress biomarkers than bacteria. The study identified 74 fungal species with significant associations compared to only 49 bacterial species, suggesting the mycobiome is a major player in redox homeostasis. Specifically, the abundance of fungal genera Alternaria and Pichia correlated with key metabolites and the expression of pro-apoptotic genes like Fas and Tnfsf10.
Pathway Convergence and Bioactive Components
SBE works through several convergent pathways to provide systemic protection:
- Gut Barrier Integrity: SBE treatment restored gut barrier integrity by upregulating tight junction proteins such as E-cadherin and Claudin-1.
- Serotonergic Synapse Pathway: SBE significantly downregulated four pivotal metabolites in this pathway (e.g., 5-HIAA and Prostaglandin C2) that were spiked by ethanol, reducing the production of H₂O₂ during serotonin metabolism.
- Apoptotic Signaling: SBE effectively suppressed the ethanol-induced over-expression of Fas and Tnfsf10 (key "death receptor" genes) to prevent cell death in the liver and brain.
Molecular docking identified trigonelline, mesaconic acid, and salicylic acid as bioactive "keys" that physically bind to Fas and Tnfsf10 proteins, providing a structural basis for SBE's anti-apoptotic effects.
Tissue and Biomarker Restoration
SBE treatment significantly lowered pro-oxidative markers (MDA, 8-isoprostane, and Protein Carbonyl) and boosted antioxidant enzymes (SOD, CAT, and GSH-Px) across the serum, intestine, liver, and brain. Histological analysis confirmed that SBE reversed ethanol-induced hippocampal neuronal degeneration and reduced hepatic lipid vacuolization.
Discussion and Future Directions
While the multi-omics correlations are robust, the authors acknowledge that the specific roles of individual microbial metabolites require further functional validation, such as fecal microbiota transplants or isolated metabolite dosing. Additionally, the metabolic fate and bioavailability of SBE's bioactive compounds after oral ingestion remain to be fully characterized. Future human clinical trials are necessary to determine if SBE could be developed into a functional food or supplement for managing acute or chronic oxidative stress disorders.
This summary is based on research published in Microbiome (2025).
Summary updated